LENZ Therapeutics (LENZ) Stock Price, News & Analysis

Company Overview

LENZ Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing pharmaceutical therapies for presbyopia, the age-related loss of near vision. The company’s approach is designed to improve near visual acuity by using aceclidine, a miotic agent intended to create a pinhole effect that can increase depth of focus while preserving distance vision.

LENZ’s lead product candidate, VIZZ, is an aceclidine hydrochloride ophthalmic solution developed as a once-daily prescription eye drop for adults with presbyopia. The company has evaluated VIZZ in late-stage clinical studies and has focused its development and regulatory efforts primarily on the U.S. ophthalmic market. LENZ’s pipeline has also included additional aceclidine-based and combination formulations intended to address near-vision impairment.

LENZ Therapeutics was established to advance topical ophthalmic treatments that could offer an alternative to reading glasses, contact lenses, or surgical procedures for people with presbyopia. The company is headquartered in San Diego, California, and is led by Chief Executive Officer Eef Schimmelpennink. Its activities have centered on clinical development, regulatory submissions, and preparation for potential commercialization of its presbyopia treatment portfolio.

Key Stats

• Today's Range: $3.46 to $3.60
• 50-Day Range: $3.58 to $5.96
• 52-Week Range: $3.45 to $49.25
• Volume: 777,357 shs
• Average Volume: 742,125 shs
• Market Capitalization: $112.80 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $28.80
• Consensus Rating: Moderate Buy

LENZ Therapeutics Stock Analysis - MarketRank™

LENZ Therapeutics scored higher than 47% of companies evaluated by MarketBeat, and ranked 544th out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

LENZ Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 5 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

LENZ Therapeutics has a consensus price target of $28.80, representing about 702.2% upside from its current price of $3.59.

Amount of Analyst Coverage

LENZ Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for LENZ Therapeutics are expected to grow in the coming year, from ($4.18) to ($3.22) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of LENZ Therapeutics is -0.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of LENZ Therapeutics is -0.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

LENZ Therapeutics has a P/B Ratio of 0.39. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

36.89% of the float of LENZ Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

LENZ Therapeutics has a short interest ratio ("days to cover") of 14.55, which indicates bearish sentiment.

Change versus previous month

Short interest in LENZ Therapeutics has recently decreased by 2.25%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

LENZ Therapeutics does not currently pay a dividend.

Dividend Growth

LENZ Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for LENZ Therapeutics this week, compared to 4 articles on an average week.

Search Interest

Only 1 people have searched for LENZ on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added LENZ Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days.

Company Ownership

• Score: 0.9 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, LENZ Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

8.30% of the stock of LENZ Therapeutics is held by insiders.

Percentage Held by Institutions

54.32% of the stock of LENZ Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/11/2026
• Today: 10/05/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:LENZ
• Previous Symbol: NASDAQ:LENZ
• CIK: 1815776
• Web: www.lenz-tx.com
• Phone: (858) 925-7000
• Fax: N/A
• Employees: 152
• Year Founded: 2013

Price Target and Rating

• Average Price Target for LENZ Therapeutics: $28.80
• High Price Target: $50.00
• Low Price Target: $7.00
• Potential Upside/Downside: +702.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($4.09)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$82.13 million
• Net Margins: -586.74%
• Pretax Margin: -586.72%
• Return on Equity: -53.39%
• Return on Assets: -49.14%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 13.55
• Quick Ratio: 13.31

Sales & Book Value

• Annual Sales: $19.09 million
• Price / Sales: 5.91
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $9.09 per share
• Price / Book: 0.39

Miscellaneous

• Outstanding Shares: 31,420,000
• Free Float: 28,812,000
• Market Cap: $112.80 million
• Optionable: N/A
• Beta: 0.64